EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 54 / No 2 (June 2022) J Extra Corpor Technol, 54 2 (2022) 115-122 References
Free Access
Issue
J Extra Corpor Technol
Volume 54, Number 2, June 2022
Page(s) 115 - 122
DOI https://doi.org/10.1051/ject/202254115
Published online 15 June 2022
  1. Dalton HJ, Garcia-Filion P, Holubkov R, et al. Association of bleeding and thrombosis with outcome in extracorporeal life support. Pediatr Crit Care Med. 2015;16:167–74. [CrossRef] [PubMed] [Google Scholar]
  2. Bembea MM, Annich G, Rycus P, et al. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: An international survey. Pediatr Crit Care Med. 2013;14:e77–84. [CrossRef] [PubMed] [Google Scholar]
  3. Hirsh J, Anand SS, Halperin JL, et al. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol. 2001;21:1094–6. [CrossRef] [PubMed] [Google Scholar]
  4. Extracorporeal Life Support Organization. ELSO Anticoagulation Guidelines. 2014 [cited 2021 June 28]. Available at: https://www.elso.org/Portals/0/Files/elsoanticoagulationguideline8-2014-table-contents.pdf. Accessed June 12, 2021. [Google Scholar]
  5. Padhya DR, Prutsky GJ, Nemergut ME, et al. Routine laboratory measures of heparin anticoagulation for children on extracorporeal membrane oxygenation: Systematic review and meta-analysis. Thromb Res. 2019;179:132–9. [CrossRef] [Google Scholar]
  6. Newall F. Anti-factor Xa (anti-Xa) assay. Methods Mol Biol. 2013;992:265–72. [CrossRef] [PubMed] [Google Scholar]
  7. Baird CW, Zurakowski D, Robinson B, et al. Anticoagulation and pediatric extracorporeal membrane oxygenation: Impact of activated clotting time and heparin dose on survival. Ann Thorac Surg. 2007;83:912–9, discussion 9–20. [CrossRef] [Google Scholar]
  8. Perry R, Stein J, Young G, et al. Antithrombin III administration in neonates with congenital diaphragmatic hernia during the first three days of extracorporeal membrane oxygenation. J Pediatr Surg. 2013;48:1837–42. [CrossRef] [Google Scholar]
  9. Niebler RA, Christensen M, Berens R, et al. Antithrombin replacement during extracorporeal membrane oxygenation. Artif Organs. 2011;35:1024–8. [CrossRef] [Google Scholar]
  10. Wong TE, Nguyen T, Shah SS, et al. Antithrombin concentrate use in pediatric extracorporeal membrane oxygenation: A multicenter cohort study. Pediatr Crit Care Med. 2016;17:1170–8. [CrossRef] [PubMed] [Google Scholar]
  11. Cleophas TJ. Clinical trials: Spline modeling is wonderful for nonlinear effects. Am J Ther. 2016;23:e844–9. [CrossRef] [PubMed] [Google Scholar]
  12. McLean MW, Hooker G, Staicu AM, et al. Functional feneralized additive models. J Comput Graph Stat. 2014;23:249–69. [CrossRef] [PubMed] [Google Scholar]
  13. Richardson B, Fuller-Tyszkiewicz M, O’Donnell R, et al. Regression tree analysis of ecological momentary assessment data. Health Psychol Rev. 2017;11:235–41. [CrossRef] [PubMed] [Google Scholar]
  14. Rigatti SJ. Random Forest. J Insur Med. 2017;47:31–9. [CrossRef] [PubMed] [Google Scholar]
  15. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing. 2022. Available at: https://www.R-project.org. [Google Scholar]
  16. Nankervis CA, Preston TJ, Dysart KC, et al. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J. 2007;53:111–4. [CrossRef] [PubMed] [Google Scholar]
  17. Bembea MM, Schwartz JM, Shah N, et al. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO J. 2013;59:63–8. [CrossRef] [PubMed] [Google Scholar]
  18. Deshpande SJ, Vitali S, Thiagarajan R, et al. Coagulations studies do not correlate with each other or with hematologic complications during pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2021;22:542–52. [CrossRef] [PubMed] [Google Scholar]
  19. Liveris A, Bello RA, Friedmann P, et al. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation. Pediat Crit Care Med. 2014;15:e72–9. [CrossRef] [PubMed] [Google Scholar]
  20. McMichael ABV, Hornik CP, Hupp SR, et al. Correlation among antifactor Xa, activated partial thromboplastin time, and heparin dose and association with pediatric extracorporeal membrane oxygenation complications. ASAIO J. 2020;66:307–13. [CrossRef] [PubMed] [Google Scholar]
  21. Saini A, Spinella PC. Management of anticoagulation and hemostasis for pediatric extracorporeal membrane oxygenation. Clin Lab Med. 2014;34:655–73. [CrossRef] [Google Scholar]
  22. Winter WE, Flax SD, Harris NS. Coagulation testing in the core laboratory. Lab Med. 2017;48:295–313. [CrossRef] [PubMed] [Google Scholar]
  23. Khan J, Chandler WL. Interference in the anti-Xa heparin activity assay due to hemolysis and icterus during pediatric extracorporeal life support. Artif Organs. 2019;43:880–7. [CrossRef] [PubMed] [Google Scholar]
  24. Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006;95:362–72. [CrossRef] [PubMed] [Google Scholar]
  25. Favaloro EJ, Lippi G. Translational aspects of developmental hemostasis: Infants and children are not miniature adults and even adults may be different. Ann Transl Med. 2017;5:212. [CrossRef] [Google Scholar]
  26. Hundalani SG, Nguyen KT, Soundar E, et al. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2014;15:e198–205. [CrossRef] [PubMed] [Google Scholar]
  27. Vieira A, Berry L, Ofosu F, et al. Heparin sensitivity and resistance in the neonate: An explanation. Thromb Res. 1991;63:85–98. [CrossRef] [Google Scholar]
  28. Stovitz SD, Shrier I. Causal inference for clinicians. BMJ Evid Based Med. 2019;24:109–12. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.